Pulmotherapeutics Inc. leverages a proprietary technology platform aimed at efficiently delivering therapeutic agents directly to the lungs in the form of inhaled therapies. This approach enhances drug delivery efficiency, reduces systemic side effects, and improves patient convenience compared to traditional treatment methods.

• ·Efficient drug delivery to the lungs
• ·Reduced systemic side effects
• ·Improved patient convenience through inhalation
• ·Proprietary technology platform